Plain-English translation of NCT04903119 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This study is testing whether adding a medication called nilotinib to your current melanoma treatment plan could help fight your cancer more effectively. The trial combines nilotinib with two existing drug combinations that are already used to treat melanoma. Researchers want to understand the right dose and safety of this three-drug approach for patients whose cancer has progressed or stopped responding to standard two-drug therapy.
Many patients with this type of melanoma eventually stop responding to current medications, and their cancer starts growing again. This trial explores whether the new treatment could help overcome that resistance and improve outcomes for people in this difficult situation.
You likely qualify if…
You likely don't qualify if…
You would start by taking two existing melanoma medications daily for one week, then add the new medication (nilotinib) in gradually increasing doses depending on which dose level you are assigned to. You'll have regular study visits, blood tests to check how the drugs interact in your body, and imaging scans to monitor your cancer. The trial also includes biopsies (small tissue samples) at the start and after two weeks of the three-drug combination to help researchers understand how the treatment is working.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
United States